Tag: in vivo contract research organization market growth

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

In Vivo Contract Research Organization Market Revenue Growth Supported By A CAGR Of 7.77% Through 2030

The market for in vivo contract research organizations has experienced robust expansion lately, projecting a rise from $5.23 billion in 2025 to $5.68 billion in 2026, reflecting a compound annual growth rate of 8.6%. This upward trajectory during the past period is attributable to heightened pharmaceutical research and development expenditures, the broadening of biotechnology portfolios, the increasing intricate nature of drug development processes, elevated regulatory demands for preclinical information, and the accessibility of sophisticated animal models.

The market for contract research organizations specializing in in vivo studies anticipates a significant expansion over the upcoming years, projecting a rise to $7.77 billion by the year 2030, underpinned by a compound annual growth rate of 8.1%. This anticipated ascent is fueled by several key factors, including a heightened need for accelerated drug development schedules, a greater utilization of sophisticated in vivo models for disease research, the burgeoning scope of investigations into oncology and rare diseases, the increasing integration of artificial intelligence in preclinical data analysis, and more stringent regulatory oversight concerning safety information. Furthermore, several prominent trends are expected to shape this market during the forecast period, such as a greater tendency for companies to outsource their preclinical research endeavors, an elevated requirement for highly specific disease models, a broader acceptance of toxicology studies adhering to Good Laboratory Practice (GLP) standards, the development of more comprehensive preclinical service packages, and a magnified emphasis on ensuring the caliber and replicability of research data.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25790&type=smp

In Vivo Contract Research Organization Market Development Factors: Which Trends Are Supporting Demand?

The increasing emphasis on personalized medicine is anticipated to fuel the expansion of the in vivo contract research organization sector. This approach to healthcare customizes treatment and preventative measures based on an individual’s genetic predispositions, habits, and surroundings to enhance health results. The heightened attention to personalized medicine stems from the greater availability and lower cost of genetic sequencing technologies, which facilitates more precise pinpointing of genetic alterations. This leads to the development of bespoke treatments that improve patient results and minimize trial-and-error procedures. Consequently, the demand within the in vivo CRO market is escalating as specialized preclinical investigations utilizing particular animal models are required to assess targeted therapies and their impact on unique genetic makeups, directly spurred by the trend toward personalized medicine. Evidence of this trend is seen in February 2024, with the Personalized Medicine Coalition (PMC) reporting that the FDA sanctioned 16 new personalized treatments in 2023, a significant increase from the six approved in 2022, marking the fourth consecutive year that personalized medicines represented over a third of all novel drug approvals by the U.S. Food and Drug Administration (FDA). Thus, the burgeoning interest in personalized medicine is a key driver for the growth of the in vivo contract research organization market.

In Vivo Contract Research Organization Market Segment Analysis Highlighting Growth Areas

The in vivo contract research organization market covered in this report is segmented –

1) By Type: Rodent Based, Non-Rodent Based

2) By Type Of Service: Translational And IND-Enabling In Vivo Studies, Preclinical Services, Post-Approval Nonclinical Safety And Mechanistic Studies

3) By Good Laboratory Practice Type: Good Laboratory Practice Toxicology, Non Good Laboratory Practice

4) By Applications: Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Other Applications

5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Government And Regulatory Bodies

Subsegments:

1) By Rodent-Based: Mice Models, Rat Models, Genetically Engineered Rodents, Immunodeficient Rodents, Humanized Rodents

2) By Non-Rodent-Based: Canine Models, Non-Human Primate Models, Swine Models, Rabbit Models, Zebrafish Models

In Vivo Contract Research Organization Market Transformation Trends: Which Innovations Are Driving Change?

Leading players within the in vivo contract research organization sector are prioritizing the creation of novel approaches, including sophisticated incubator programs for advanced therapies, with the aim of expediting the progression of cutting-edge treatments and facilitating foundational clinical investigations. These advanced therapy incubator programs represent targeted endeavors established to assist emerging biotechnology firms by furnishing them with essential resources, expert guidance, and the necessary facilities to expedite the advancement of groundbreaking treatments like gene, cell, and RNA therapies. As an illustration, in April 2025, Charles River Laboratories International Inc., a corporate entity headquartered in the United States, initiated its inaugural group for an advanced therapy incubator program. This forward-thinking program is structured to provide assistance to early-stage biotechnology ventures concentrating on the development of next-generation therapeutic modalities. Participants in this program are afforded opportunities to leverage Charles River’s scientific acumen, its cutting-edge laboratory facilities, and tailored in vivo models, thereby empowering them to quickly produce initial supporting data. Furthermore, the program offers a practical preclinical environment for the validation of potential therapeutic agents, contributing to a reduction in the timeframe required to reach clinical trials and enhancing the probability of achieving regulatory approval. This strategic effort serves as a vital conduit between scientific discovery and clinical application, significantly contributing to the progress of the advanced therapeutics landscape.

In Vivo Contract Research Organization Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the in vivo contract research organization market are Thermo Fisher Scientific Inc, Labcorp Drug Development Inc, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc, Evotec SE, GemPharmatech Co Ltd, BIOQUAL Inc, Crown Bioscience Inc, PsychoGenics Inc, Janvier Labs SAS, Taconic Bioscience Inc, Xentech SAS, Altogen Labs Inc, AniLocus Inc, Pharmaron Beijing Co Ltd, Southern Research Institute, SRI International, Envigo RMS LLC, Horizon Discovery Group plc, Inotiv Inc, GenScript ProBio

Access The Complete In Vivo Contract Research Organization Market Report:

https://www.thebusinessresearchcompany.com/report/in-vivo-contract-research-organization-global-market-report

In Vivo Contract Research Organization Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the in vivo contract research organization market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the in vivo contract research organization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The In Vivo Contract Research Organization Market By 2030?

The in vivo contract research organization market has experienced significant growth in its size over recent years. The market is anticipated to expand from $5.23 billion in 2025 to $5.68 billion in 2026, at a compound annual growth rate (CAGR) of 8.6%. Historically, this expansion has been driven by increased spending on pharmaceutical research and development, the growth in biotechnology pipelines, the escalating complexity of drug development processes, more rigorous regulatory mandates for preclinical data, and the accessibility of advanced animal models.

The in vivo contract research organization market size is poised for substantial growth over the next few years, with projections indicating an increase to $7.77 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period can be primarily linked to several factors: a heightened urgency for quicker drug development timelines, the increased adoption of advanced in vivo disease models, the broader scope of research into oncology and rare diseases, the growing integration of AI-enabled preclinical analytics, and more rigorous regulatory examination of safety data. Significant trends anticipated during this period include a greater reliance on outsourcing for preclinical research activities, a rising necessity for specialized disease models, the broader implementation of GLP-compliant toxicology studies, an expansion of comprehensive preclinical service offerings, and a sharpened focus on data integrity and reproducibility.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25790&type=smp

What Primary Factors Are Fueling The Expansion Of The In Vivo Contract Research Organization Market?

The expansion of the in vivo contract research organization market is anticipated to be fueled by the increasing emphasis on personalized medicine. This medical approach customizes treatment and prevention strategies for individuals based on their genetic profile, lifestyle, and environmental factors, aiming to improve health outcomes. The heightened attention to personalized medicine stems from the enhanced accessibility and reduced cost of genomic sequencing technologies, which facilitate a more precise identification of genetic mutations, leading to the development of specific therapies that enhance patient results and minimize inefficient treatment trials. Consequently, this increasing focus on personalized medicine is boosting demand within the in vivo CRO market, necessitating tailored preclinical studies utilizing particular animal models to assess targeted therapies and their impact on unique genetic profiles. For example, data from February 2024, provided by the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the FDA sanctioned 16 new personalized treatments in 2023, marking an increase from six in 2022. Furthermore, personalized medicines constituted more than one-third of all novel drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year. This sustained emphasis on personalized medicine is, therefore, accelerating the expansion of the in vivo contract research organization market.

What Are The Core Segment Classifications In The In Vivo Contract Research Organization Market?

The in vivo contract research organization market covered in this report is segmented –

1) By Type: Rodent Based, Non-Rodent Based

2) By Type Of Service: Translational And IND-Enabling In Vivo Studies, Preclinical Services, Post-Approval Nonclinical Safety And Mechanistic Studies

3) By Good Laboratory Practice Type: Good Laboratory Practice Toxicology, Non Good Laboratory Practice

4) By Applications: Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Other Applications

5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Government And Regulatory Bodies

Subsegments:

1) By Rodent-Based: Mice Models, Rat Models, Genetically Engineered Rodents, Immunodeficient Rodents, Humanized Rodents

2) By Non-Rodent-Based: Canine Models, Non-Human Primate Models, Swine Models, Rabbit Models, Zebrafish Models

Which Trends Are Influencing The Expansion Of The In Vivo Contract Research Organization Market?

Leading companies within the in vivo contract research organization market are focusing on creating novel solutions, such as advanced therapy incubator programs, to accelerate the progression of next-generation therapeutics and support initial clinical research. An advanced therapy incubator program serves as a specialized initiative crafted to assist early-stage biotechnology enterprises by providing essential resources, mentorship, and infrastructure, thereby accelerating the development of advanced therapies, including gene, cell, and RNA-based treatments. For instance, in April 2025, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced its inaugural advanced therapy incubator program cohort. This innovative program aims to support nascent biotech companies dedicated to developing future therapies. Through this initiative, participants gain access to Charles River’s scientific proficiency, advanced laboratory facilities, and customized in vivo models, enabling them to swiftly generate proof-of-concept data. The program further provides a realistic preclinical setting for validating therapeutic candidates, helping to shorten the timeline to clinical trials and enhance the prospects of regulatory approval. By connecting academic breakthroughs with clinical progression, this initiative plays a vital role in advancing the field of advanced therapies.

Who Are The Leading Firms Participating In The In Vivo Contract Research Organization Market?

Major companies operating in the in vivo contract research organization market are Thermo Fisher Scientific Inc, Labcorp Drug Development Inc, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc, Evotec SE, GemPharmatech Co Ltd, BIOQUAL Inc, Crown Bioscience Inc, PsychoGenics Inc, Janvier Labs SAS, Taconic Bioscience Inc, Xentech SAS, Altogen Labs Inc, AniLocus Inc, Pharmaron Beijing Co Ltd, Southern Research Institute, SRI International, Envigo RMS LLC, Horizon Discovery Group plc, Inotiv Inc, GenScript ProBio

Access The Complete In Vivo Contract Research Organization Market Report:

https://www.thebusinessresearchcompany.com/report/in-vivo-contract-research-organization-global-market-report

Which Region Stands As The Largest Contributor To The In Vivo Contract Research Organization Market?

North America was the largest region in the in vivo contract research organization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vivo contract research organization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access In Vivo Contract Research Organization Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=25790&type=smp

Browse Through More Reports Similar to the Global In Vivo Contract Research Organization Market 2026, By The Business Research Company

Biologics Contract Development Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Medical Device Contract Manufacturing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-device-contract-manufacturing-global-market-report

Contract Development Manufacturing Organizations Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/contract-development-manufacturing-organizations-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The In Vivo Contract Research Organization Market Expected To Reach Based On Its 2026 Value?

The in vivo contract research organization market has experienced robust growth recently. Projections indicate that this market will expand from $5.23 billion in 2025 to $5.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.6%. This historical expansion is primarily due to factors such as increased investment in pharmaceutical research and development, the broadening of biotechnology pipelines, the rising intricacy of drug development processes, stricter regulatory demands for preclinical information, and the accessibility of sophisticated animal models.

The in vivo contract research organization market is anticipated to show significant expansion in the upcoming years. It is projected to climb to $7.77 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This projected increase during the forecast period is fueled by several factors, including an escalating demand for quicker drug development timelines, the growing utilization of advanced in vivo disease models, the expansion of research in oncology and rare diseases, the increasing adoption of AI-enabled preclinical analytics, and heightened regulatory scrutiny of safety data. Prominent trends for this period encompass the rising outsourcing of preclinical research activities, an increasing need for specialized disease models, the wider acceptance of GLP-compliant toxicology studies, the development of more integrated preclinical service offerings, and a sharpened focus on data quality and reproducibility.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/in-vivo-contract-research-organization-global-market-report

What Key Drivers Are Fueling The Growth Of The In Vivo Contract Research Organization Market?

The increasing emphasis on personalized medicine is expected to drive the growth of the in vivo contract research organization market going forward. Personalized medicine is a medical approach that customizes treatment and prevention strategies to an individual’s genetic makeup, lifestyle, and environment to optimize health outcomes. This heightened focus on personalized medicine is attributed to the increasing accessibility and affordability of genomic sequencing technologies, as these advancements enable more accurate identification of genetic mutations, facilitating tailored therapies that improve patient outcomes and reduce trial-and-error in treatment. The growing focus on personalized medicine is therefore boosting demand in the in vivo CRO market, as customized preclinical studies using specific animal models are essential to evaluate targeted therapies and their effects on distinct genetic profiles. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the FDA approved 16 new personalized treatments in 2023, which was up from six in 2022. Personalized medicines made up more than one-third of all new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year. Consequently, the expanding focus on personalized medicine is propelling the growth of the in vivo contract research organization market.

What Segment Categories Shape The In Vivo Contract Research Organization Market Segment Landscape?

The in vivo contract research organization market covered in this report is segmented –

1) By Type: Rodent Based, Non-Rodent Based

2) By Type Of Service: Translational And IND-Enabling In Vivo Studies, Preclinical Services, Post-Approval Nonclinical Safety And Mechanistic Studies

3) By Good Laboratory Practice Type: Good Laboratory Practice Toxicology, Non Good Laboratory Practice

4) By Applications: Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Other Applications

5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Government And Regulatory Bodies

Subsegments:

1) By Rodent-Based: Mice Models, Rat Models, Genetically Engineered Rodents, Immunodeficient Rodents, Humanized Rodents

2) By Non-Rodent-Based: Canine Models, Non-Human Primate Models, Swine Models, Rabbit Models, Zebrafish Models

What Trends Are Influencing The In Vivo Contract Research Organization Market?

Major companies operating in the in vivo contract research organization market are focusing on developing innovative solutions, such as advanced therapy incubator programs, to accelerate the development of next-generation therapeutics and support early-stage clinical research. An advanced therapy incubator program is a specialized initiative designed to support early-stage biotechnology companies by providing resources, mentorship, and infrastructure to accelerate the development of advanced therapies such as gene, cell, and RNA-based treatments. For instance, in April 2025, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched its inaugural advanced therapy incubator program cohort. This innovative initiative is designed to support early-stage biotech companies focused on developing next-generation therapies. Through the program, participants gain access to Charles River’s scientific expertise, state-of-the-art laboratory infrastructure, and customized in vivo models, enabling them to rapidly generate proof-of-concept data. The program also provides a real-world preclinical setting for validating therapeutic candidates, helping to shorten time-to-clinic and improve the likelihood of regulatory success. By bridging the gap between academic innovation and clinical development, the initiative plays a crucial role in advancing the field of advanced therapies.

Who Are The Companies Operating Across The In Vivo Contract Research Organization Market Value Chain?

Major companies operating in the in vivo contract research organization market are Thermo Fisher Scientific Inc, Labcorp Drug Development Inc, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc, Evotec SE, GemPharmatech Co Ltd, BIOQUAL Inc, Crown Bioscience Inc, PsychoGenics Inc, Janvier Labs SAS, Taconic Bioscience Inc, Xentech SAS, Altogen Labs Inc, AniLocus Inc, Pharmaron Beijing Co Ltd, Southern Research Institute, SRI International, Envigo RMS LLC, Horizon Discovery Group plc, Inotiv Inc, GenScript ProBio

Get The Full In Vivo Contract Research Organization Market Report:

https://www.thebusinessresearchcompany.com/report/in-vivo-contract-research-organization-global-market-report

Which Region Is The Top Contributor To The In Vivo Contract Research Organization Market By Share?

North America was the largest region in the in vivo contract research organization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vivo contract research organization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized In Vivo Contract Research Organization Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/in-vivo-contract-research-organization-global-market-report

Browse Through More Reports Similar to the Global In Vivo Contract Research Organization Market 2026, By The Business Research Company

Contract Development Manufacturing Organizations Market Report 2026

https://www.thebusinessresearchcompany.com/report/contract-development-manufacturing-organizations-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Medical Device Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-device-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The In Vivo Contract Research Organization Market During The Forecast Period 2026–2030?

The in vivo contract research organization market size has demonstrated significant growth in recent years. It is anticipated to increase from $5.23 billion in 2025 to $5.68 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.6%. This historical expansion can be linked to factors like rising pharmaceutical R&D spending, the broadening of biotechnology pipelines, the increasing complexity inherent in drug development, stricter regulatory mandates for preclinical data, and the availability of sophisticated animal models.

The in vivo contract research organization market size is projected to experience robust expansion over the coming years. It is anticipated to reach $7.77 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This projected growth during the forecast period stems from factors such as increasing demand for faster drug development timelines, rising use of advanced in vivo disease models, expansion of oncology and rare disease research, growing adoption of AI-enabled preclinical analytics, and increasing regulatory scrutiny of safety data. Significant trends expected in this forecast period include increasing outsourcing of preclinical research activities, rising demand for specialized disease models, growing adoption of GLP-compliant toxicology studies, expansion of integrated preclinical service offerings, and an enhanced focus on data quality and reproducibility.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25790&type=smp

What Underlying Factors Are Accelerating The Growth Of The In Vivo Contract Research Organization Market?

The expanding emphasis on personalized medicine is projected to drive the expansion of the in vivo contract research organization market in the future. This medical strategy involves customizing treatment and prevention methods based on an individual’s genetic profile, lifestyle choices, and environmental factors to enhance health results. This heightened attention to personalized medicine stems from the improved accessibility and cost-effectiveness of genomic sequencing technologies. These technological advancements facilitate more precise detection of genetic mutations, which in turn allows for customized treatments that lead to better patient outcomes and minimize experimental approaches in therapy. The increasing concentration on personalized medicine is fueling demand within the in vivo CRO market, given the necessity for bespoke preclinical studies employing particular animal models to assess targeted therapies and their impact on unique genetic profiles. For example, data from February 2024, provided by the Personalized Medicine Coalition (PMC), a US-based nonprofit, revealed that the FDA sanctioned 16 new personalized treatments in 2023, a rise from six in 2022. For the fourth consecutive year, personalized medicines constituted over one-third of all novel drug approvals by the U.S. Food and Drug Administration (FDA). Consequently, the intensifying focus on personalized medicine is a key driver for the growth of the in vivo contract research organization market.

What Market Segments Are Evaluated Within The In Vivo Contract Research Organization Market?

The in vivo contract research organization market covered in this report is segmented –

1) By Type: Rodent Based, Non-Rodent Based

2) By Type Of Service: Translational And IND-Enabling In Vivo Studies, Preclinical Services, Post-Approval Nonclinical Safety And Mechanistic Studies

3) By Good Laboratory Practice Type: Good Laboratory Practice Toxicology, Non Good Laboratory Practice

4) By Applications: Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Other Applications

5) By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Government And Regulatory Bodies

Subsegments:

1) By Rodent-Based: Mice Models, Rat Models, Genetically Engineered Rodents, Immunodeficient Rodents, Humanized Rodents

2) By Non-Rodent-Based: Canine Models, Non-Human Primate Models, Swine Models, Rabbit Models, Zebrafish Models

Which Market Trends Are Creating New Opportunities In The In Vivo Contract Research Organization Market?

Leading companies within the in vivo contract research organization market are concentrating on developing innovative solutions, such as advanced therapy incubator programs, to accelerate the progress of next-generation therapeutics and support early-stage clinical research. An advanced therapy incubator program represents a specialized undertaking designed to assist early-stage biotechnology companies by providing resources, mentorship, and infrastructure to speed up the development of advanced therapies like gene, cell, and RNA-based treatments. For instance, in April 2025, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched its inaugural advanced therapy incubator program cohort. This pioneering initiative is designed to support early-stage biotech companies focused on evolving next-generation therapies. Through the program, participants gain access to Charles River’s scientific expertise, state-of-the-art laboratory infrastructure, and customized in vivo models, enabling them to rapidly generate proof-of-concept data. The program also offers a practical preclinical setting for validating therapeutic candidates, helping to shorten time-to-clinic and improve the likelihood of regulatory success. By bridging the gap between academic innovation and clinical development, this initiative plays a crucial role in advancing the field of advanced therapies.

Who Are The Top Market Participants Influencing The In Vivo Contract Research Organization Market?

Major companies operating in the in vivo contract research organization market are Thermo Fisher Scientific Inc, Labcorp Drug Development Inc, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc, Evotec SE, GemPharmatech Co Ltd, BIOQUAL Inc, Crown Bioscience Inc, PsychoGenics Inc, Janvier Labs SAS, Taconic Bioscience Inc, Xentech SAS, Altogen Labs Inc, AniLocus Inc, Pharmaron Beijing Co Ltd, Southern Research Institute, SRI International, Envigo RMS LLC, Horizon Discovery Group plc, Inotiv Inc, GenScript ProBio

Read the full in vivo contract research organization market report here:

https://www.thebusinessresearchcompany.com/report/in-vivo-contract-research-organization-global-market-report

Which Region Is Projected To Dominate The In Vivo Contract Research Organization Market During The Forecast Period?

North America was the largest region in the in vivo contract research organization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vivo contract research organization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored In Vivo Contract Research Organization Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25790&type=smp

Browse Through More Reports Similar to the Global In Vivo Contract Research Organization Market 2026, By The Business Research Company

Biologics Contract Development Global Market Report

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Medical Device Contract Manufacturing Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-device-contract-manufacturing-global-market-report

Contract Development Manufacturing Organizations Global Market Report

https://www.thebusinessresearchcompany.com/report/contract-development-manufacturing-organizations-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model